ZimuGongMDPhD
Hematology • Oklahoma City, OKHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Physician
Dr. Gong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
800 NE 10th St
Oklahoma City, OK 73104Phone+1 405-271-8299Fax+1 405-271-8490
Summary
- Zimu Gong, MD is a Oklahoma city-based Hematologist. Dr. Gong completed residency in Internal Medicine at Ascension Illinois/Saint Joseph and fellowship in Hematology and Medical Oncology at Houston Methodist Hospital. His professional journey includes a tenure as a Graduate Student Researcher at the University of Texas M.D. Anderson Cancer Center. He has an impressive list of publications to his credit on various aspects of oncology, with some even being cited by other publications.
Education & Training
Methodist Hospital (Houston)Fellowship, Hematology and Medical Oncology, 2021 - 2024
Ascension Illinois/Saint Joseph (Chicago)Residency, Internal Medicine, 2018 - 2021
China Medical University ShenyangClass of 2013
Certifications & Licensure
OK State Medical License 2024 - 2025
TX State Medical License 2021 - 2024
IL State Medical License 2018 - 2021- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 32 citationsCytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.Zimu Gong, L. Jeffrey Medeiros, Jorge E. Cortes, Zi Chen, Lan Zheng
Blood Advances. 2017-12-12 - 3 citationsAdverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study.Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin
Blood Cancer Journal. 2024-03-05 - 144 citationsOutcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.Hamzah Abu-Sbeih, Faisal Ali, Dana Alsaadi, Joseph Jennings, Wenyi Luo
Journal for Immunotherapy of Cancer. 2018-12-05
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
